Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma

Clinical Cancer Research

Volumn 9, Issue 3, 2003, Pages 998-1008

  Butterfield, Lisa H ^a   Ribas, Antoni ^a   Dissette, Vivian B ^a   Amarnani, Saral N ^a   Vu, Huong T ^a   Oseguera, Denise ^a   Wang, He Jing ^a   Elashoff, Robert M ^a   McBride, William H ^a   Mukherji, Bijay ^b   Cochran, Alistair J ^a   Glaspy, John A ^a   Economou, James S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; TETRAMER;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; MALE; MELANOMA; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TOXICITY TESTING; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD8; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERFERON TYPE II; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE BIOSYNTHESIS; PEPTIDES; TREATMENT OUTCOME;

EID: 0037343272     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Sercarz, E. E. Driver clones and determinant spreading [see comments]. J. Autoimmun., 14: 275-277, 2000.
2. Farris, A. D., Keech, C. L., Gordon, T. P., and McCluskey, J. Epitope mimics and determinant spreading: pathways to autoimmunity. Cell. Mol. Life Sci., 57: 569-578, 2000.
3. Powell, A. M., and Black, M. M. Epitope spreading: protection from pathogens, but propagation of autoimmunity? Clin. Exp. Dermatol., 26: 427-433, 2001.
4. Lehmann, P. V., Forsthuber, T., Miller, A., and Sercarz, E. E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature (Lond.), 358: 155-157, 1992.
5. McRae, B. L., Vanderlugt, C. L., Dal Canto, M. C., and Miller, S. D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med., 182: 75-85, 1995.
6. Yu, M., Johnson, J. M., and Tuohy, V. K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med., 183: 1777-1788, 1996.
7. Vanderlugt, C. J., and Miller, S. D. Epitope spreading. Curr. Opin. Immunol., 8: 831-836, 1996.
8. Lehmann, P. V., Sercarz, E. E., Forsthuber, T., Dayan, C. M., and Gammon, G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol. Today, 14: 203-208, 1993.
9. Kaufman, D. L., Clare-Salzler, M., Tian, J., Forsthuber, T., Ting, G. S., Robinson, P., Atkinson, M. A., Sercarz, E. E., Tobin, A. J., and Lehmann, P. V. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature (Lond.), 366: 69-72, 1993.
10. Tisch, R., Yang, X. D., Singer, S. M., Liblau, R. S., Fugger, L., and McDevitt, H. O., Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature (Lond.), 366: 72-75, 1993.
11. Tian, J., Olcott, A. P., Hanssen, L. R., Zekzer, D., Middleton, B., and Kaufman, D. L. Infectious Th1 and Th2 autoimmunity in diabetes-prone mice. Immunol. Rev., 164: 119-127, 1998.
12. Tuohy, V. K., Yu, M., Yin, L., Kawczak, J. A., Johnson, J. M., Mathisen, P. M., Weinstock-Guttman, B., and Kinkel, R. P. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev., 164: 93-100, 1998.
13. Markiewicz, M. A., Fallarino, F., Ashikari, A., and Gajewski, T. F. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int. Immunol., 13: 625-632, 2001.
14. el-Shami, K., Tirosh, B., Bar-Haim, E., Carmon, L., Vadai, E., Fridkin, M., Feldman, M., and Eisenbach, L. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur. J. Immunol., 29: 3295-3301, 1999.
15. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Wash. DC), 264: 961-965, 1994.
16. Sigal, L. J., Crotty, S., Andino, R., and Rock, K. L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature (Lond.), 398: 77-80, 1999.
17. Huang, A. Y., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med., 183: 769-776, 1996.
18. Albert, M. L., Sauter, B., and Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (Lond.), 392: 86-89, 1998.
19. Mitchell, D. A., Nair, S. K., and Gilboa, E. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. Eur. J. Immunol., 28: 1923-1933, 1998.
20. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med., 188: 1359-1368, 1998.
21. Butterfield, L. H., Meng, W. S., Koh, A., Vollmer, C. M., Ribas, A., Dissette, V. B., Faull, K., Glaspy, J. A., McBride, W. H., and Economou, J. S. T cell responses to HLA-A*0201-restricted peptides derived from human α fetoprotein. J. Immunol., 166: 5300-5308, 2001.
22. Zarour, H. M., Kirkwood, J. M., Kierstead, L. S., Herr, W., Brusic, V., Slingluff, C. L., Jr., Sidney, J., Sette, A., and Storkus, W. J. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc. Natl. Acad. Sci. USA, 97: 400-405, 2000.
23. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science (Wash. DC), 264: 716-719, 1994.
24. Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. Melanocyte lineagespecific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179: 1005-1009, 1994.
25. Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Buschenfelde, K. H., and Boon, T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24: 759-764, 1994.
26. van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., De Smet, C., Traversari, C., Townsend, A., and Boon, T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24: 3038-3043, 1994.
27. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trock-enbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
28. Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Wash. DC), 274: 94-96, 1996.
29. Mayer, S., Scheibenbogen, C., Lee, K. H., Keilholz, W., Stevanovic, S., Rammensee, H. G., and Keilholz, U. A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J. Immunol. Methods, 197: 131-137, 1996.
30. Herr, W., Schneider, J., Lohse, A. W., Meyer zum Buschenfelde, K. H., and Wolfel, T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods, 191: 131-142, 1996.
31. Butterfield, L. H., Koh, A., Meng, W., Vollmer, C. M., Ribas, A., Dissette, V., Lee, E., Glaspy, J. A., McBride, W. H., and Economou, J. S. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from α-fetoprotein. Cancer Res., 59: 3134-3142, 1999.
32. Carter, L. L., and Swain, S. L. Single cell analyses of cytokine production. Curr. Opin. Immunol., 9: 177-182, 1997.
33. Plebanski, M., Allsopp, C. E., Aidoo, M., Reyburn, H., and Hill, A. V. Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur. J. Immunol., 25: 1783-1787, 1995.
34. Butterfield, L. H., Jilani, S. M., Chakraborty, N. G., Bui, L. A., Ribas, A., Dissette, V. B., Lau, R., Gamradt, S. C., Glaspy, J. A., McBride, W. H., Mukherji, B., and Economou, J. S. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol., 161: 5607-5613, 1998.
35. Banchereau, J., Palucka, K., Dhodpkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taket, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., Pineiro, L., Steinman, R., and Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res., 61: 6451-6458, 2001.
36. Lau, R., Wang, F., Jeffery, G., Marty, V., Kuniyoshi, J., Bade, E., Ryback, M. E., and Weber, J. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother., 24: 66-78, 2001.
37. Lee, K. H., Wang, E., Nielsen, M. B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol., 163: 6292-6300, 1999.
38. Mackensen, A., Herbst, B., Chen, J. L., Kohler, G., Noppen, C., Herr, W., Spagnoli, G. C., Cerundolo, V., and Lindemann, A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer, 86: 385-392, 2000.
39. Panelli, M. C., Wunderlich, J., Jeffries, J., Wang, E., Mixon, A., Rosenberg, S. A., and Marincola, F. M. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother., 23: 487-498, 2000.
40. Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Brocker, E. B., Steinman, R. M., Enk, A., Kampgen, E., and Schuler, G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-de-rived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med., 190: 1669-1678, 1999.
41. Sadanaga, N., Nagashima, H., Mashino, K., Tahara, K., Yamaguchi, H., Ohta, M., Fujie, T., Tanaka, F., Inoue, H., Takesako, K., Akiyoshi, T., and Mori, M. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res., 7: 2277-2284, 2001.
42. Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuges, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., Marty, V., and Weber, J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol., 19: 3836-3847, 2001.
43. Nielsen, M. B., Monsurro, V., Migueles, S. A., Wang, E., Perez-Diez, A., Lee, K. H., Kammula, U., Rosenberg, S. A., and Marincola, F. M. Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol., 165: 2287-2296, 2000.
44. Slingluff, C. L., Jr., Yamshchikov, G., Neese, P., Galavotti, H., Eastham, S., Engelhard, V. H., Kittlesen, D., Deacon, D., Hibbitts, S., Grosh, W. W., Petroni, G., Cohen, R., Wiernasz, C., Patterson, J. W., Conway, B. P., and Ross, W. G. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res., 7: 3012-3024, 2001.
45. Jager, E., Hohn, H., Necker, A., Forster, R., Karbach, J., Freitag, K., Neukirch, C., Castelli, C., Salter, R. D., Knuth, A., and Maeurer, M. J. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int. J. Cancer, 98: 376-388, 2002.
46. Ranieri, E., Kierstead, L. S., Zarour, H., Kirkwood, J. M., Lotze, M. T., Whiteside, T., and Storkus, W. J. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol. Investig., 29: 121-125, 2000.
47. Jonuleit, H., Giesecke-Tuettenberg, A., Tuting, T., Thurner-Schuler, B., Stuge, T. B., Paragnik, L., Kandemir, A., Lee, P. P., Schuler, G., Knop, J., and Enk, A. H. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer, 93: 243-251, 2001.
48. Lally, K. M., Mocellin, S., Ohnmacht, G. A., Nielsen, M. B., Bettinotti, M., Panelli, M. C., Monsurro, V., and Marincola, F. M. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer, 93: 841-847, 2001.
49. Rosenberg, S. A., and White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphas. Tumor Immunol., 19: 81-84, 1996.
50. Rosenberg, S. A., Kawakami, Y., Robbins, P. F., and Wang, R. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv. Cancer Res., 70: 145-177, 1996.
51. Boon, T., De Plaen, E., Lurquin, C., Van den Eynde, B., van der Bruggen, P., Traversari, C., Amar-Costesec, A., and Van Pel, A. Identification of tumour rejection antigens recognized by T lymghocytes. Cancer Surv., 13: 23-37, 1992.
52. Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
53. Tian, J., Gregori, S., Adorini, L., and Kaufman, D. L. The frequency of high avidity T cells determines the hierarchy of determinant spreading. J. Immunol., 166: 7144-7150, 2001.
54. Tuohy, V. K., Yu, M., Yin, L., Kawczak, J. A., and Kinkel, R. P. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med., 189: 1033-1042, 1999.
55. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and Davis, M. M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
56. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
57. Mukherji, B., Chakraborty, N. G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J. R., Kurtzman, S. K., Ergin, M. T., Ozols, J., Meehan, J., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA, 92: 8078-8082, 1995.
58. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic, cells. Nat. Med., 2: 52-58, 1996.
59. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]. Nat. Med., 4: 328-332, 1998.
60. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Jarisch, J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate, 38: 73-78, 1999.
61. Morse, M. A., Deng, Y., Coleman, D., Hull, S., Kitrell-Fisher, E., Nair, S., Schlom, J., Ryback, M. E., and Lyerly, H. K. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res., 5: 1331-1338, 1999.
62. Cull, G., Durrant, L., Stainer, C., Haynes, A., and Russell, N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br. J. Haematol., 107: 648-655, 1999.
63. Lim, S. H., and Bailey-Wood, R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer, 83: 215-222, 1999.
64. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., and Valone, F. H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells [see comment in J. Clin. Oncol., 18: 3879-3882, 2000]. J. Clin. Oncol., 18: 3894-3903, 2000.
65. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., and Engleman, E. G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA, 98: 8809-8814, 2001.
66. Fong, L., Brockstedt, D., Benike, C., Wu, L., and Engleman, E. G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol., 166: 4254-4259, 2001.
67. Toungouz, M., Libin, M., Bulte, F., Faid, L., Lehmann, F., Duriau, D., Laporte, M., Gangji, D., Bruyns, C., Lambermont, M., Goldman, M., and Velu, T. Transient expansion of peptide-specific lymphocytes producing IFN-γ after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J. Leukocyte Biol., 69: 937-943, 2001.
68. Nishiyama, T., Tachibana, M., Horiguchi, Y., Nakamura, K., Ikeda, Y., Takesako, K., and Murai, M. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin. Cancer Res., 7: 23-31, 2001.
69. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.
70. Porgador, A., and Gilboa, E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med., 182: 255-260, 1995.
71. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., and Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med., 193: 233-238, 2001.
72. Gallucci, S., Lolkema, M., and Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med., 5: 1249-1255, 1999.
73. Steinman, R. M., Pack, M., and Inaba, K. Dendritic cell development and maturation. Adv. Exp. Med. Biol., 417: 1-6, 1997.
74. Barratt-Boyes, S. M., Zimmer, M. I., Harshyne, L. A., Meyer, E. M., Watkins, S. C., Capuano, S., III, Murphey-Corb, M., Falo, L. D., Jr., and Donnenberg, A. D. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J. Immunol., 164: 2487-2495, 2000.